

Supplementary tables and figures

Supplementary Table 1 – General characteristics of the study population ¹

| | Total population (n=546) |
|---|---------------------------------|
| Age (years) | 60 ± 7 |
| Sex (%men) | 61 |
| NGM/IGM/T2DM (%) | 52/23/25 |
| BMI (kg/m ²) | 29 ± 4 |
| Waist circumference (cm) | 99 ± 12 |
| Systolic blood pressure (mmHg) | 140 ± 19 |
| Diastolic blood pressure (mmHg) | 82 ± 9 |
| Fasting plasma glucose (mmol/L) | 5.6 [5.2-6.4] |
| HbA1c (%) | 6.0 ± 0.8 |
| eGFR (ml/min/1.73cm ²) ² | 91.1 ± 18.4 |
| Triglycerides (mmol/L) | 1.4 [1.0-2.0] |
| Total cholesterol (mmol/L) | 5.2 ± 1.0 |
| HDL cholesterol (mmol/L) | 1.2 ± 0.3 |
| Anti-hypertensive medication (%) | 38 |
| Lipid-mediating medication (%) | 19 |
| Glucose-lowering medication (%) | 13 |
| Total activity score (10 ³ METs/week) | 5.9 [3.7-8.7] |
| Current smokers (%) | 23 |
| Total alcohol intake (g/d) | 8.5 [1.3-22.5] |
| Total energy intake (kcal/d) | 2213 ± 666 |
| Plasma D-lactate and MGO | |
| Fasting plasma D-lactate (μmol/L) | 8.7 [6.3-12.9] |
| Fasting plasma MGO (nmol/L) | 366.3 ± 77.8 |
| iAUC MGO during OGTT | 9413 [4042-14525] |
| Plasma AGEs | |
| Fasting plasma free CEL (nmol/L) | 45.4 [36.6-58.4] |
| Fasting plasma free MG-H1 (nmol/L) | 123.6 [86.6-172.6] |
| Fasting plasma protein-bound CEL (nmol/mmol lysine) | 23.1 [18.7-28.9] |
| Urinary AGEs and D-lactate | |
| Urinary CEL (nmol/mmol creatinine) | 517 [408-642] |
| Urinary MG-H1 (nmol/mmol creatinine) | 2266 [1593-3300] |
| Urinary D-lactate (nmol/mmol creatinine) | 0.8 [0.4-1.7] |

¹Data are presented as mean ± standard deviation for normally distributed variables, median (interquartile range) for skewed variables or proportion (%) for categorical variables.

²Calculated using the Modification of Diet in Renal Disease (MDRD) formula.

AGE, advanced glycation endproduct; CEL, Nε-(1-carboxyethyl)lysine; eGFR, estimated glomerular filtration rate; iAUC MGO, incremental area under the curve of MGO after an oral glucose tolerance test; IGM, impaired glucose metabolism; MG-H1, Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine; MGO, methylglyoxal; NGM, normal glucose metabolism; OGTT, oral glucose tolerance test; T2DM, type 2 diabetes.

Supplementary table 2 – Means of Glo1 mRNA and markers of MGO stress for each of the three genotypes of the nine SNPs

| SNP | Genotype | Glo1 expression | | Plasma MGO and D-lactate | | | | Plasma AGEs | | | | Urinary AGEs and D-lactate | | | | | |
|--------------------|----------|-----------------|--------------------|--------------------------|------------|------------------|-----|----------------------------|-----|-----------------|--------------------------|----------------------------|-----|------------------|----------------------|-----|---------------------|
| | | n | Glo1 mRNA | n | Plasma MGO | Plasma D-lactate | n | iAUC MGO post-OGTT (units) | n | Plasma free CEL | Plasma protein-bound CEL | Plasma free MG-H1 | n | Urinary CEL | Urinary MG-H1 | n | Urinary D-lactate |
| SNP4 rs3199033 | AA | 355 | 0.95 [0.74-1.2] | 423 | 366 ± 78 | 8.4 [6.4-12] | 376 | 9.8 [4.1-15] | 423 | 45 [37-57] | 23 [19-29] | 123 [85-173] | 396 | 512 [405-629] | 2292 [1596-3202] | 398 | 0.78 [0.38-1.6] |
| | AT | 82 | 0.82 [0.58-1.0] | 102 | 365 ± 72 | 9.5 [5.6-14] | 93 | 8.1 [3.5-13] | 102 | 46 [38-60] | 24 [19-31] | 118 [87-157] | 97 | 532 [443-707] | 2141 [1603-3331] | 97 | 0.78 [0.44-2.1] |
| | TT | 7 | 0.82 [0.59-1.0] | 7 | 426 ± 72 | 9.1 [4.7-15] | 6 | 6.4 [1.4-9.9] | 7 | 60 [35-71] | 21 [15-25] | 158 [63-211] | 7 | 547 [323-832] | 2046 [1239-3557] | 7 | 0.35 [0.27-1.8] |
| SNP13 rs3799703 | GG | 121 | 0.86 [0.60-1.1] | 148 | 363 ± 73 | 7.9 [5.4-11] | 140 | 8.4 [2.7-14] | 148 | 46 [36-59] | 23 [19-29] | 122 [87-168] | 141 | 484 [424-662] | 2274 [1551-3330] | 141 | 0.75 [0.38-1.7] |
| | AG | 206 | 0.93 [0.71-1.2] | 249 | 368 ± 82 | 9.0 [7.0-14] | 216 | 9.4 [4.2-15] | 249 | 45 [36-56] | 23 [19-29] | 120 [85-170] | 237 | 520 [397-642] | 2217 [1586-3459] | 239 | 0.81 [0.39-1.8] |
| | AA | 110 | 0.97 [0.76-1.2] | 126 | 368 ± 74 | 7.9 [5.9-7.9] | 111 | 11 [4.6-15] | 126 | 45 [39-57] | 27 [19-29] | 123 [89-169] | 115 | 522 [401-623] | 2165 [1593-3032] | 115 | 0.80 [0.38-1.5] |
| SNP16 rs2736655 | GG | 326 | 0.92 [0.68-1.1] | 397 | 368 ± 80 | 8.7 [6.4-13] | 354 | 8.9 [4.0-14] | 397 | 45 [36-58] | 23 [19-29] | 121 [85-170] | 374 | 511 [405-639] | 2274 [1569-3368] | 376 | 0.80 [0.38-1.7] |
| | AG | 107 | 1.0 [0.73-1.2] | 127 | 365 ± 72 | 8.9 [6.4-14] | 113 | 10 [4.0-16] | 127 | 46 [38-59] | 24 [19-29] | 129 [91-193] | 120 | 532 [418-652] | 2208 [1649-3264] | 120 | 0.85 [0.40-1.7] |
| | AA | 11 | 0.96 [0.78-1.3] | 11 | 349 ± 51 | 7.3 [5.4-12] | 10 | 8.5 [4.6-13] | 11 | 41 [35-63] | 27 [20-29] | 135 [82-173] | 9 | 429 [429-522] | 2358 [1888-2605] | 9 | 0.58 [0.41-2.5] |
| SNP18 rs2736654 | TT | 135 | 0.92 [0.74-1.2] | 161 | 376 ± 73 | 9.3 [6.2-12] | 143 | 9.9 [4.8-14] | 161 | 46 [39-59] | 24 [20-30] | 121 [87-178] | 149 | 525 [397-657] | 2165 [1596-3246] | 149 | 0.77 [0.43-1.4] |
| | GT | 230 | 0.94 [0.68-1.2] | 277 | 363 ± 80 | 8.5 [6.4-14] | 242 | 8.8 [4.1-15] | 277 | 45 [36-57] | 22 [18-27] | 126 [88-170] | 262 | 516 [405-636] | 2263 [1666-3315] | 265 | 0.81 [0.36-2.1] |
| | GG | 80 | 0.90 [0.70-1.2] | 98 | 363 ± 73 | 8.3 [6.5-11] | 93 | 9.5 [2.4-15] | 98 | 47 [36-59] | 24 [19-30] | 115 [85-176] | 92 | 492 [419-665] | 2311 [1497-3477] | 91 | 0.77 [0.40-1.6] |
| SNP28 rs3778443 | GG | 381 | 0.92 [0.71-1.2] | 458 | 366 ± 70 | 8.5 [6.2-13] | 412 | 9.5 [4.2-15] | 458 | 46 [37-58] | 23 [19-29] | 124 [88-171] | 428 | 518 [409-642] | 2292 [1588-3281] | 430 | 0.79 [0.38-1.7] |
| | AG | 63 | 1.0 [0.68-1.3] | 76 | 375 ± 82 | 9.7 [6.8-13] | 63 | 8.6 [3.7-15] | 76 | 48 [38-60] | 23 [19-29] | 126 [84-194] | 73 | 519 [399-654] | 2126 [16449-3489] | 73 | 0.75 [0.36-1.4] |
| | AA | 4 | 1.0 [0.71-1.4] | 4 | 382 ± 30 | 9.5 [5.9-20] | 4 | 6.7 [-1.6-16] | 4 | 48 [35-69] | 24 [20-28] | 110 [87-218] | 4 | 482 [350-540] | 2479 [1244-3212] | 4 | 0.54 [0.35-0.93] |

| SNP | Genotype | Glo1 expression | | Plasma MGO and D-lactate | | | | | Plasma AGEs | | | | Urinary AGEs and D-lactate | | | | |
|---------------------|----------|-----------------|--------------------|--------------------------|------------|------------------|-----|----------------------------|-------------|-----------------|--------------------------|-------------------|----------------------------|-------------------|---------------------|-----|---------------------|
| | | n | Glo1 mRNA | n | Plasma MGO | Plasma D-lactate | n | iAUC MGO post-OGTT (units) | n | Plasma free CEL | Plasma protein-bound CEL | Plasma free MG-H1 | n | Urinary CEL | Urinary MG-H1 | n | Urinary D-lactate |
| SNP38 rs1781716 | GG | 354 | 0.93 [0.71-1.2] | 428 | 365 ± 77 | 8.4 [6.2-13] | 386 | 9.1 [4.0-14] | 428 | 45 [36-58] | 23 [19-29] | 121 [89-173] | 402 | 517 [405-638] | 2292 [1584-3259] | 402 | 0.78 [0.38-1.7] |
| | CG | 79 | 0.94 [0.68-1.3] | 96 | 372 ± 81 | 9.6 [6.8-13] | 81 | 10 [4.2-14] | 96 | 49 [37-60] | 23 [19-29] | 132 [85-180] | 90 | 528 [416-665] | 2126 [1662-3637] | 92 | 0.81 [0.47-1.5] |
| | CC | 4 | 1.0 [0.71-1.4] | 4 | 382 ± 30 | 9.5 [5.9-20] | 4 | 6.7 [1.6-16] | 4 | 48 [35-69] | 24 [20-28] | 110 [87-219] | 4 | 482 [350-540] | 2474 [1244-3123] | 4 | 0.54 [0.35-0.93] |
| SNP40 rs10484854 | CC | 223 | 0.94 [0.73-1.2] | 273 | 369 ± 75 | 9.0 [6.2-13] | 242 | 9.5 [4.2-15] | 273 | 46 [38-58] | 24 [19-30] | 120 [88-170] | 252 | 525 [401-646] | 2252 [1664-3263] | 254 | 0.81 [0.44-1.7] |
| | CT | 194 | 0.93 [0.66-1.2] | 226 | 364 ± 79 | 8.5 [6.5-13] | 201 | 9.3 [3.9-16] | 226 | 44 [36-58] | 23 [19-29] | 126 [84-171] | 216 | 511 [415-635] | 2228 [1532-3142] | 216 | 0.77 [0.35-1.7] |
| | TT | 28 | 0.84 [0.73-1.1] | 35 | 374 ± 83 | 8.3 [5.9-12] | 33 | 7.9 [16-12] | 35 | 50 [35-59] | 24 [19-30] | 143 [85-205] | 33 | 441 [384-567] | 2291 [1370-3505] | 33 | 0.47 [0.28-1.2] |
| SNP45 rs17622621 | GG | 163 | 1.0 [0.78-1.2] | 199 | 367 ± 74 | 8.8 [6.2-12] | 174 | 10 [4.2-15] | 199 | 45 [38-59] | 24 [18-29] | 120 [89-170] | 181 | 525 [406-650] | 2310 [1746-3213] | 183 | 0.84 [0.44-1.6] |
| | AG | 212 | 0.88 [0.67-1.2] | 252 | 367 ± 82 | 8.5 [6.5-13] | 226 | 9.5 [4.3-15] | 252 | 44 [36-55] | 23 [19-29] | 118 [80-170] | 241 | 511 [410-632] | 2219 [1482-3265] | 241 | 0.79 [0.38-1.7] |
| | AA | 66 | 0.86 [0.70-1.1] | 77 | 369 ± 71 | 8.7 [5.8-14] | 72 | 7.3 [3.4-12] | 77 | 51 [39-63] | 24 [19-30] | 130 [88-175] | 73 | 511 [410-706] | 2187 [1559-3377] | 73 | 0.50 [0.33-1.7] |
| SNP49 rs1049346 | AA | 112 | 0.90 [0.68-1.1] | 135 | 365 ± 74 | 8.8 [6.4-13] | 122 | 8.3 [3.8-12] | 135 | 50 [36-63] | 23 [19-29] | 126 [86-184] | 127 | 511 [419-6845] | 2125 [1667-3489] | 128 | 0.62 [0.35-1.6] |
| | AG | 240 | 0.94 [0.66-1.2] | 284 | 370 ± 80 | 8.8 [6.5-13] | 254 | 9.4 [4.0-15] | 284 | 44 [37-55] | 23 [19-29] | 126 [84-170] | 272 | 520 [408-637] | 2327 [1500-3416] | 272 | 0.79 [0.38-1.7] |
| | GG | 94 | 0.97 [0.78-1.2] | 117 | 364 ± 74 | 8.2 [6.0-13] | 101 | 10 [4.1-16] | 117 | 45 [37-59] | 23 [18-28] | 119 [89-170] | 104 | 526 [406-663] | 2319 [1909-3174] | 105 | 0.91 [0.48-1.8] |


¹Data are presented as mean ± standard deviation for normally distributed variables and median [interquartile range] for skewed variables

AGE, advanced glycation endproduct; CEL, Nε-(1-carboxyethyl)lysine; iAUC MGO, incremental area under the curve of MGO after an oral glucose tolerance test; MG-H1, Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine; MGO, methylglyoxal; OGTT, oral glucose tolerance test; SNP, single nucleotide polymorphism

Supplementary table 3 - Associations between iAUC MGO after an OGTT and SNPs of GLO1 using logistic regression

| SNP | N | Genotype | iAUC MGO (low/high) | |
|--------------------|-----|----------|---------------------|------|
| | | | OR | p |
| SNP4 (rs3199033) | 475 | AA | - | - |
| | | AT | 0.82 | 0.40 |
| | | TT | 0.39 | 0.32 |
| SNP13 (rs3799703) | 467 | GG | - | - |
| | | AG | 1.00 | 0.99 |
| | | AA | 1.38 | 0.24 |
| SNP16 (rs2736655) | 477 | GG | - | |
| | | AG | 1.24 | 0.35 |
| | | AA | 1.45 | 0.57 |
| SNP18 (rs2736654) | 478 | TT | - | |
| | | GT | 0.82 | 0.36 |
| | | GG | 0.89 | 0.68 |
| SNP28 (rs3778443) | 479 | GG | - | - |
| | | AG | 1.01 | 0.99 |
| | | AA | 0.30 | 0.33 |
| SNP38 (rs1781716) | 471 | GG | - | - |
| | | CG | 1.23 | 0.40 |
| | | CC | 0.32 | 0.36 |
| SNP40 (rs10484854) | 476 | CC | - | - |
| | | CT | 0.90 | 0.60 |
| | | TT | 0.98 | 0.96 |
| SNP45 (rs17622621) | 472 | GG | - | - |
| | | AG | 0.91 | 0.66 |
| | | AA | 0.72 | 0.26 |
| SNP49 (rs1049346) | 477 | AA | - | - |
| | | AG | 1.30 | 0.26 |
| | | GG | 1.48 | 0.17 |

Odds ratios of logistic regression, using a categorical variable of iAUC MGO (below/above median) as outcome variable and the three genotypes (dummy variables with major homozygous as reference) as main independent variable. Odds ratio indicates the odds of having a MGO concentration above the median for the stated genotype compared to the reference genotype. Results are displayed for fully adjusted model (adjusted for age, sex and glucose metabolism status). iAUC: incremental area under the curve. MGO: methylglyoxal. OR: Odds ratio.



Supplementary Figure 1 – Flowchart of CODAM study population